Quantcast

Industry news that matters to you.  Learn more

Quintiles Announces Suite of PI3K Biomarker Assays to Advance Oncology Therapies Targeting this Cancer Pathway

Quintiles today announced a comprehensive suite of biomarker assays to help bio pharmaceutical companies investigate the phosphoinositide 3-kinases (PI3K) cancer survival pathway, the focus of numerous anti-cancer therapies under development. Understanding the PI3K pathway is essential in developing new medicines to inhibit or block this pathway, thereby cutting off a metabolic function needed for certain cancers to survive.

Duke, LabCorp Launch ‘Factory’ to Translate Biomarkers into Personalized Medicine Tests

If a factory is where raw components are manufactured and assembled into commercial products, then why not take a similar approach to developing diagnostics to predict disease predisposition and response to drugs?

Duke University and the Laboratory Corporation of America have put their collective expertise together to create just such an enterprise, which they’ve dubbed the Biomarker Factory. The project, announced earlier this month, enjoins Duke University Medical Center’s expertise in biomarker discovery and LabCorp’s capacity to develop laboratory-developed tests from validated biomarkers.